Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 3 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 3 COMBINATION PACK.
FULVICIN P/G 165 vs MICONAZOLE 3 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and fungal cell death.
165 mg orally once daily.
Intravaginal: 1 applicatorful (100 mg) at bedtime for 3 consecutive nights.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal elimination half-life is 20-25 hours (intravaginal administration). This long half-life supports a 3-day dosing regimen, maintaining therapeutic concentrations.
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Renal: approximately 10-20% as unchanged drug; fecal: >50% as metabolites; biliary: minor route. The majority is eliminated via feces as metabolites, reflecting hepatic metabolism and biliary excretion.
Category C
Category A/B
Antifungal
Antifungal